List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Ovarian Cancer. 12 results shown below.
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study

Principal Investigator: Heidi Gray, MD

Study Number: 7750

Phase: Pilot



Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Complete title: Anti-PD-1 Therapy in Combination with Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Principal Investigator: John Liao

Study Number: 9740

Phase: I/II



IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
Complete title: A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery

Principal Investigator: John Liao

Study Number: 9760

Phase: II



Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Complete title: Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?

Principal Investigator: Heidi Gray, MD

Study Number: GOG 0225

Phase: III



Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Principal Investigator: Heidi Gray, MD

Study Number: S1609

Phase: II



Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)
Complete title: A Phase 1A/1B Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

Principal Investigator: John Thompson, MD

Study Number: 20151981

Phase: I



Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Principal Investigator: Gabriela Chiorean

Study Number: 20152369

Phase: II



Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)
Complete title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Principal Investigator: Heidi Gray, MD

Study Number: 20152389

Phase: I/II



ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Complete title: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20162178

Phase: III



Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
Complete title: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20162888

Phase: II



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Elizabeth Loggers

Study Number: 9612

Phase: II



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Erin Pinto

Study Number: SC-4008

Phase: II



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials